BACKGROUND: Protein glycosylation is a common posttranslational modification and glycan structural changes have been observed in several malignancies including prostate cancer. We hypothesized that altered glycosylation could be related to differences in gene expression levels of glycoprotein synthetic enzymes between normal and malignant prostate tissues. METHODS: We interrogated prostate cancer gene expression data for reproducible changes in expression of glycoprotein synthetic enzymes. Over-expression of GCNT1 was validated in prostate samples using RT-PCR. ELISA was used to measure core 2 O-linked glycan sialyl Lewis X (sLe(x) ) of prostate specific antigen (PSA), Mucin1 (MUC1), and prostatic acidic phosphatase (PAP) proteins. RESULTS: A key glycosyltransferase, GCNT1, was consistently over-expressed in several prostate cancer gene expression datasets. RT-PCR confirmed increased transcript levels in cancer samples compared to normal prostate tissue in fresh-frozen prostate tissue samples. ELISA using PSA, PAP, and MUC1 capture antibodies and a specific core 2 O-linked sLe(x) detection antibody demonstrated elevation of this glycan structure in cancer compared to normal tissues for MUC1 (P = 0.01), PSA (P = 0.03) and near significant differences in PAP sLe(x) levels (P = 0.06). MUC1, PSA and PAP protein levels alone were not significantly different between paired normal and malignant prostate samples. CONCLUSIONS: GCNT1 is over-expressed in prostate cancer and is associated with higher levels of core 2 O-sLe(x) in PSA, PAP and MUC1 proteins. Alterations of O-linked glycosylation could be important in prostate cancer biology and could provide a new avenue for development of prostate cancer specific glycoprotein biomarkers.
BACKGROUND: Protein glycosylation is a common posttranslational modification and glycan structural changes have been observed in several malignancies including prostate cancer. We hypothesized that altered glycosylation could be related to differences in gene expression levels of glycoprotein synthetic enzymes between normal and malignant prostate tissues. METHODS: We interrogated prostate cancer gene expression data for reproducible changes in expression of glycoprotein synthetic enzymes. Over-expression of GCNT1 was validated in prostate samples using RT-PCR. ELISA was used to measure core 2 O-linked glycan sialyl Lewis X (sLe(x) ) of prostate specific antigen (PSA), Mucin1 (MUC1), and prostatic acidic phosphatase (PAP) proteins. RESULTS: A key glycosyltransferase, GCNT1, was consistently over-expressed in several prostate cancer gene expression datasets. RT-PCR confirmed increased transcript levels in cancer samples compared to normal prostate tissue in fresh-frozen prostate tissue samples. ELISA using PSA, PAP, and MUC1 capture antibodies and a specific core 2 O-linked sLe(x) detection antibody demonstrated elevation of this glycan structure in cancer compared to normal tissues for MUC1 (P = 0.01), PSA (P = 0.03) and near significant differences in PAP sLe(x) levels (P = 0.06). MUC1, PSA and PAP protein levels alone were not significantly different between paired normal and malignant prostate samples. CONCLUSIONS:GCNT1 is over-expressed in prostate cancer and is associated with higher levels of core 2 O-sLe(x) in PSA, PAP and MUC1 proteins. Alterations of O-linked glycosylation could be important in prostate cancer biology and could provide a new avenue for development of prostate cancer specific glycoprotein biomarkers.
Authors: Jacques Lapointe; Chunde Li; John P Higgins; Matt van de Rijn; Eric Bair; Kelli Montgomery; Michelle Ferrari; Lars Egevad; Walter Rayford; Ulf Bergerheim; Peter Ekman; Angelo M DeMarzo; Robert Tibshirani; David Botstein; Patrick O Brown; James D Brooks; Jonathan R Pollack Journal: Proc Natl Acad Sci U S A Date: 2004-01-07 Impact factor: 11.205
Authors: Dinesh Singh; Phillip G Febbo; Kenneth Ross; Donald G Jackson; Judith Manola; Christine Ladd; Pablo Tamayo; Andrew A Renshaw; Anthony V D'Amico; Jerome P Richie; Eric S Lander; Massimo Loda; Philip W Kantoff; Todd R Golub; William R Sellers Journal: Cancer Cell Date: 2002-03 Impact factor: 31.743
Authors: Catherine A St Hill; Mariya Farooqui; Gregory Mitcheltree; H Evin Gulbahce; Jose Jessurun; Qing Cao; Bruce Walcheck Journal: BMC Cancer Date: 2009-03-06 Impact factor: 4.430
Authors: Caroline B Madsen; Cecilie Petersen; Kirstine Lavrsen; Mikkel Harndahl; Søren Buus; Henrik Clausen; Anders E Pedersen; Hans H Wandall Journal: PLoS One Date: 2012-11-26 Impact factor: 3.240
Authors: Jan Tkac; Veronika Gajdosova; Stefania Hroncekova; Tomas Bertok; Michal Hires; Eduard Jane; Lenka Lorencova; Peter Kasak Journal: Interface Focus Date: 2019-02-15 Impact factor: 3.906
Authors: Esther Llop; Montserrat Ferrer-Batallé; Sílvia Barrabés; Pedro Enrique Guerrero; Manel Ramírez; Radka Saldova; Pauline M Rudd; Rosa N Aleixandre; Josep Comet; Rafael de Llorens; Rosa Peracaula Journal: Theranostics Date: 2016-05-24 Impact factor: 11.556
Authors: Okyaz Eminaga; Wei Wei; Sarah J Hawley; Heidi Auman; Lisa F Newcomb; Jeff Simko; Antonio Hurtado-Coll; Dean A Troyer; Peter R Carroll; Martin E Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; Jesse K McKenney; Ziding Feng; Ladan Fazli; James D Brooks Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: Jennifer Munkley; Sebastian Oltean; Daniel Vodák; Brian T Wilson; Karen E Livermore; Yan Zhou; Eleanor Star; Vasileios I Floros; Bjarne Johannessen; Bridget Knight; Paul McCullagh; John McGrath; Malcolm Crundwell; Rolf I Skotheim; Craig N Robson; Hing Y Leung; Lorna W Harries; Prabhakar Rajan; Ian G Mills; David J Elliott Journal: Oncotarget Date: 2015-10-27
Authors: Jennifer Munkley; Daniel Vodak; Karen E Livermore; Katherine James; Brian T Wilson; Bridget Knight; Paul Mccullagh; John Mcgrath; Malcolm Crundwell; Lorna W Harries; Hing Y Leung; Craig N Robson; Ian G Mills; Prabhakar Rajan; David J Elliott Journal: EBioMedicine Date: 2016-04-20 Impact factor: 8.143